US Patent 11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
Patent 11236121 was granted and assigned to SAGE Therapeutics on February, 2022 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
